Filament Health, a clinical‐stage natural psychedelic drug development company, agreed to go public via a SPAC merger with Jupiter Acquisition, a special purpose acquisition company, in a $210m deal. "We are thrilled to have the opportunity to impact the advancement of psychedelic medicines that will support the treatment of mental health conditions through this combination with Filament. Led by an exceptional management team, Filament is taking a novel approach to psychedelic drug development through natural botanical extracts. We are excited by Filament's plans for its technology, and view this opportunity as a significant value driver for our stockholders," James Hauslein, Jupiter Chairman and CEO.